Comparison of individually tailored versus fixed-schedule rituximab regimen to maintain ANCA-associated vasculitis remission: Results of a multicenter, randomized controlled, phase III trial (MAINRITSAN2)
Charles P et al. Ann Rheum Dis 2018; Advance online publication. doi: 10.1136/annrheumdis-2017-212878
Please follow the link below to view this article in full on a third-party website. Note that a subscription or payment may be required.